๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cochrane Review: Pharmacotherapy for anxiety disorders in children and adolescents

โœ Scribed by Jonathan C Ipser; Dan J Stein; Susan Hawkridge; Lara Hoppe


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
600 KB
Volume
5
Category
Article
ISSN
1557-6272

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Cochrane review: Cognitive behavioural t
โœ Dr A James; A Soler; R Weatherall ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 441 KB ๐Ÿ‘ 1 views

## Abstract ## Background Childhood and adolescent anxiety disorders are relatively common, occurring in between 5โ€18% of all children and adolescents. They are associated with significant morbidity and impairment in social and academic functioning, and when persistent, there is a risk of depressi

Commentary on โ€˜Pharmacotherapy for anxie
โœ David Cohen; Martine F. Flament; Angรจle Consoli; Jonathan C. Ipser; Susan Hawkri ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 69 KB ๐Ÿ‘ 2 views

## Abstract This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. __Cochrane Database of Systematic Reviews__ 2009, Issue 3. Art. No.: CD005170. DOI

Advances in pharmacotherapy for pediatri
โœ Moira Rynn; Anthony Puliafico; Charlotte Heleniak; Pranav Rikhi; Kareem Ghalib; ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 138 KB

Pediatric anxiety disorders are prevalent, chronic, and often lead to significant impaired functioning that impacts both short-and long-term outcomes for children and adolescents. Treatment options include pharmacotherapy and psychosocial interventions. This presentation will review treatment advanc